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Collapsin response mediator protein 1 (CRMP1) is one of the CRMP family members
that are involved in various aspects of neuronal development such as axonal
guidance and neuronal migration. Here we provide evidence that crmp1−/− mice
exhibited behavioral abnormalities related to schizophrenia. The crmp1−/− mice exhibited
hyperactivity and/or impaired emotional behavioral phenotype. These mice also exhibited
impaired context-dependent memory and long-term memory retention. Furthermore,
crmp1−/− mice exhibited decreased prepulse inhibition, and this phenotype was rescued
by administration of chlorpromazine, a typical antipsychotic drug. In addition, in vivo
microdialysis revealed that the methamphetamine-induced release of dopamine in
prefrontal cortex was exaggerated in crmp1−/− mice, suggesting that enhanced
mesocortical dopaminergic transmission contributes to their hyperactivity phenotype.
These observations suggest that impairment of CRMP1 function may be involved in
the pathogenesis of schizophrenia. We propose that crmp1−/− mouse may model
endophenotypes present in this neuropsychiatric disorder.
Keywords: CRMP1, comprehensive behavioral test, knockout mouse, schizophrenia, mesocortical dopaminergic
transmission, hyperactivity, prepulse inhibition
INTRODUCTION
Collapsin response mediator protein (CRMP) was origi-
nally identified as a signaling molecule of Semaphorin3A
(Sema3A), a repulsive axonal guidance molecule (Goshima
et al., 1995). CRMPs are now known to consist of five
homologous cytosolic proteins, CRMP1–5. All family mem-
bers are highly expressed in the developing and adult ner-
vous system (Minturn et al., 1995; Byk et al., 1996; Hamajima
et al., 1996; Wang and Strittmatter, 1996; Fukada et al.,
2000; Inatome et al., 2000; Yuasa-Kawada et al., 2003). In
cultured neurons, CRMPs have been shown to be involved
in axon specification, elongation, and navigation, suggest-
ing that they play multifunctional roles in neuronal develop-
ment. CRMPs are present as phosphoproteins in the devel-
oping nervous system (Byk et al., 1996). CRMPs bind to
tubulin heterodimer, and upon phosphorylation of CRMPs
by Rho/ROCK kinase, cyclin-dependent kinase-5 (Cdk5), and
glycogen synthase kinase-3β, the binding affinity of CRMPs to
tubulin is lowered (Fukata et al., 2002; Uchida et al., 2005;
Yoshimura et al., 2005). Thus, phosphorylation of CRMPs by
these kinases is thought to play important roles in neuronal
development (Yamashita and Goshima, 2012).
Several knockout mice studies have begun to reveal the in vivo
roles of CRMPs in neuronal development and function (Charrier
et al., 2006; Yamashita et al., 2006, 2007, 2011, 2012; Su et al.,
2007; Quach et al., 2008; Niisato et al., 2012a,b). CRMP1 regulates
neuronal cell migration, dendritic spine development, and synap-
tic plasticity in vivo (Charrier et al., 2006; Yamashita et al., 2006,
2007; Su et al., 2007). To regulate neuronal cell migration, CRMP1
is phosphorylated by Fyn, a Src-type tyrosine kinase, downstream
of Reelin (Yamashita et al., 2006). Furthermore, phosphoryla-
tion of CRMP1 by Cdk5 is essential for Sema3A-induced spine
development (Yamashita et al., 2007). These findings indicate that
CRMP1mediates signals from several extracellular molecules that
play essential roles in neuronal network formation and synapse
formation. However, the roles of CRMP1 in the regulation of
higher brain functions are largely unknown.
To address this issue, we carried out a comprehensive behav-
ioral analysis of crmp1−/− mice. We found that they exhibited
hyperactivity, impaired learning and memory, and impaired pre-
pulse inhibition. Because these phenotypes appear to be analo-
gous to some of the symptoms of schizophrenia, we propose that
crmp1−/− mouse is useful in exploring basic mechanisms that
may contribute to some of the symptoms of schizophrenia.
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MATERIALS AND METHODS
MUTANT MICE AND EXPERIMENTAL DESIGN
Wild-type (wt) and crmp1−/− mice (Charrier et al., 2006) were
generated by mating crmp1+/− heterozygotes that had been back-
crossed to the C57BL/6N background for at least seven genera-
tions. Genotypes of the offspring of all mutant mice were assessed
with the use of polymerase chain reaction, as described pre-
viously (Charrier et al., 2006). Comprehensive behavioral test
battery (Takao and Miyakawa, 2006) (except drug treatments for
the prepulse inhibition test, see below) was carried out with sin-
gle male mice that were at least 21 weeks of age. Raw data of
the behavioral test battery, the date on which each experiment
was done, and the age of the mice at the time of the exper-
iment are shown in the mouse phenotype database (Table 1;
http://www.mouse-phenotype.org/). Female mice were excluded
because their behavior is influenced by the menstrual cycle. To
minimize the effects of previous tests on subsequent tests, we per-
formed the behavioral test battery in a specific order, in which the
less stressful tests preceded the more stressful tests. Each behav-
ioral test was separated from each other at least by one day. The
order of the battery test and the summary of each test result were
described in Table 1.
Mice were housed in the standard mouse facility and fed an
autoclaved diet and water. All procedures were performed accord-
ing to the guidelines outlined in the institutional Animal Care
and Use Committee of the Yokohama City University School
of Medicine or Kyoto University Graduate School of Medicine.
Throughout the experimental procedures, all efforts were made
to minimize the number of animals used and their suffering.
TWENTY FOUR-HOUR HOME CAGE MONITORING
A system that automatically analyses behavior in home cages
was used to monitor locomotor activity (O’Hara and Co., Tokyo,
Japan) (Yamasaki et al., 2008). The system comprised the home
cage (29 × 18× 12 cm) and a filtered cage top, separated by a
13-cm high metal stand containing an infrared video camera
attached at the top of the stand. Each wt or crmp1−/− mouse
was placed in an individual home cage, and behavior was mon-
itored for 1 week. Images from each cage were captured at a rate
of one frame per second. Their locomotor activity was measured
by quantifying the number of pixels changed between successive
frames. Analysis was performed automatically using Image HA
software (O’Hara and Co.).
OPEN FIELD TEST
Each mouse was placed in the center of the open field apparatus
(40 × 40× 30 cm; Accuscan Instruments, Columbus, OH, USA).
Total distance traveled (cm), vertical activity (rearing measured
by counting the number of photobeam interruptions), time spent
in the center (20 × 20 cm), the beam-break counts for stereo-
typed behaviors, and number of fecal boli were recorded. Data
were collected for 120min.
ELEVATED PLUS MAZE
The elevated plus-maze (O’Hara and Co.) consisted of two open
arms (25 × 5 cm) and two enclosed arms of the same size, with
15-cm-high transparent walls. The arms and central square were
Table 1 | Comprehensive behavioral test battery of crmp1−/− mice.
Test Measurements Age (w) Phenotype
1. General health and
neurological screening
Body weight
Body temperature
Wire hanging time
Grip strengthen
21–25 ↓
→
→
→
2. Light/dark transition Light/dark
transition
21–25 →
3. Open field
(Figures 1B–E)
Total distance
Vertical activity
Center time
Stereotypic
counts
21–26 ↑
→
↑
→
4. Elevated plus maze
(Figures 2A,B)
Time on center
Time on close arm
21–26 ↑
↓
5. Hot plate Pain sensitivity 21–26 ↑
6. Social interaction
(novel environment)
Social behavior 22–26 →
7. Rotarod Motor
coordination
22–26 →
8. Social interaction
(Crawley ver.)
Social behavior 23–27 →
9. Prepulse inhibition
(Figures 4A,B)
Prepulse inhibition 23–27 ↓
10. Porsolt forced
swim (Figures 2C,D)
Immobility time 24–28 ↓
11. Gait analysis Locomotion
pattern
24–29 →
12. Barnes maze
(Figure 3B)
Special memory
Memory retention
25–29 →
↓
13. T-maze Working memory 32–36 →
14. Fear conditioning
(Figure 3A)
Contextual
learning
Cued learning
37–41 ↓
→
15. Tail suspension Behavioral despair 39–43 →
16. Social interaction
(home cage)
Social behavior 62–67 →
17. Home cage
monitoring (Figure 1A)
Locomotor activity 69–75 ↑
Age (w); age of weeks of subject at the beginning of each test.
→, no significant difference; ↑, increased; ↓, decreased.
made of white plastic plates and were elevated to a height of 55 cm
above the floor. To minimize the likelihood of animals falling
from the apparatus, 3-mm-high plastic ledges were provided for
the open arms. Arms of the same type were arranged at opposite
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sides to each other. Eachmouse was placed in the central square of
the maze (5 × 5 cm), facing one of the closed arms. Mouse behav-
ior was recorded for 10min. The number of entries into open
and enclosed arms, and the time spent in the central square and
open and enclosed arms were recorded. For data analysis, we used
the following measures: the percentage of entries into the open
arms, the time spent in the central square and open and enclosed
arms (sec), and total distance traveled (cm). Data acquisition and
analysis were performed automatically using Image EP software
(O’Hara and Co.).
PORSOLT FORCED SWIM
The apparatus consisted of four plastic cylinders (20 cm in height,
10 cm in diameter). The cylinders were filled with water at 23◦C
up to a height of 7.5 cm. Mice were placed into the cylinders,
and their behavior was recorded for 10min. Data acquisition and
analysis were performed automatically with Image PS software
(O’Hara and Co.).
CONTEXTUAL AND CUED FEAR CONDITIONING
Each mouse was placed in a test chamber (26 × 34× 29 cm) and
allowed to explore freely for 2min. A 55-dB white noise, which
served as the conditioned stimulus (CS), was presented for 30 s,
followed by a mild (2 s, 0.35mA) foot shock, which served as the
unconditioned stimulus (US). Two more CS-US pairings were
presented with an interstimulus interval of 2min. Context test-
ing was conducted in the same chamber 1 day after conditioning.
Cued testing with altered context was performed in a triangu-
lar box (35 × 35× 40 cm) made of white opaque Plexiglas and
located in a different room 1 day after conditioning.
Data acquisition, control of stimuli (tones and shocks), and
data analysis were performed automatically with Image FZ soft-
ware (O’Hara and Co.). Images were captured at the rate of
1 frame per second. For each pair of successive frames, the
area (number of pixels) corresponding to the movement of the
mouse was measured. If this area was below a certain thresh-
old (20 pixels), the behavior was judged as freezing. If the
area equaled or exceeded the threshold, the behavior was con-
sidered nonfreezing. The optimal threshold (number of pix-
els) for judgment of freezing was based on evaluation of the
behavior by human observation. Freezing that persisted for less
than the defined time threshold (2 s) was not included in the
analysis.
BARNES MAZE
The Barnes task was performed on dry land, a white circular sur-
face, 1.0m in diameter, with 12 holes equally spaced around the
perimeter (O’Hara and Co.). The circular open field was elevated
75 cm from the floor. A black Plexiglas escape box (17 × 13×
7 cm), the bottom of which contained paper cage bedding, was
located under one of the holes. The hole above the escape box
represented the target, analogous to the hidden platform in the
Morris task. The location of the target was consistent for a given
mouse but randomized across mice. The maze was rotated daily,
with the spatial location of the target unchanged with respect to
the distal visual room cues, to prevent bias based on olfactory
cues or the proximal cues within the maze. Three trials per day
were conducted for six successive days. On day 7, a probe trial
was performed without the escape box, to confirm that the spatial
task was acquired on the basis of navigation via the distal envi-
ronment room cues. A probe trial was also performed after 12
days of retention (day 19). The latency before the mouse reached
the target hole, distance traveled to reach the target hole, num-
ber of errors, and time spent around each hole were recorded by
video-tracking software (Image BM, O’Hara and Co.).
PREPULSE INHIBITION
A startle reflex measurement system (O’Hara and Co.) was used
to measure startle response and prepulse inhibition. The test ses-
sion began by placing a mouse in a plastic cylinder and leaving it
undisturbed for 10min. White noise (40ms) was used as the star-
tle stimulus for all trial types. The startle response was recorded
for 140ms (with measurement of the response every 1ms) begin-
ning with the onset of the prepulse stimulus. The background
noise level in each chamber was 70 dB. The peak startle ampli-
tude recorded during the 140-ms sampling window was used
as the dependent variable. A test session consisted of six trial
types (two types of startle stimulus only trial, and four types
of prepulse inhibition trial). The intensity of the startle stimu-
lus was 110 or 120 dB. The prepulse sound (74 or 78 dB) was
presented 100ms before the startle stimulus. Four combinations
of prepulse and startle stimuli were used (74 and 110, 78 and
110, 74, and 120, and 78, and 120 dB). Six blocks of the six trial
types were presented in pseudorandom order such that each trial
type was presented once within a block. The average intertrial
interval was 15 s (range, 10–20 s). For drug treatments, 12-week-
old crmp1−/− mice were placed in a startle reflex measurement
system 5min after intraperitoneal injection of chlorpromazine
(1mg/kg, Mitsubishi Tanabe Pharma, Osaka, Japan) or saline.
IN VIVO MICRODIALYSIS
In vivo microdialysis measurements of extracellular dopamine
were performed in freely moving mice (Jitsuki et al., 2011).
Mice were anesthetized with isoflurane and a guide cannula
(AG-4; EICOM, Kyoto, Japan) was implanted stereotaxically
into the medial prefrontal cortex. The coordinates were 2mm
anterior from the bregma, 0.3mm lateral to the midline, and
1.5mm below the surface of the brain according to the atlas of
Franklin and Paxinos (Franklin and Paxinos, 2007). Two days
after the surgery, a dialysis probe (AI-4-1, 1mm membrane
length; EICOM) was inserted through the guide cannula and was
perfused at a flow rate of 1.0μl/min with artificial cerebrospinal
fluid (147mM NaCl, 4mM KCl, 1.2mM CaCl2, 0.9mM MgCl2).
Sample collection was started after a 2-hr equilibration period.
The outflow fractions were collected every 20min. After collec-
tion of six baseline fractions, mice were treated with metham-
phetamine (1mg/kg, i.p., Dainippon Sumitomo Pharma, Osaka,
Japan) and sampling was continued for an additional 180min.
The amount of dopamine in the dialysis fractions was measured
by high-performance liquid chromatography on a VA5-ODS col-
umn (EICOM) that was maintained at 25◦C and equipped with
an electrochemical detection system (ECD-300, EICOM). The
changes in electric current (nA) were recorded using an integrated
data processor (Chromatocorder 12; System Instruments Co.,
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Tokyo, Japan). The dopamine concentration in the dialysate was
calculated by reference to the peak area of the standard solution.
The probe locations were verified histologically.
IMAGE ANALYSIS
The applications used for the behavioral studies (Image HA,
Image EP, Image PS, Image FZ, and Image BM) were based on the
NIH Image program (developed at the U.S. National Institutes
of Health and available at http://rsb.info.nih.gov/nih-image) and
ImageJ program (http://rsb.info.nih.gov/ij), which weremodified
for each test by T. Miyakawa and are available through O’Hara
and Co. Image EP (Komada et al., 2008) and Image FZ are freely
available at the following URL: http://www.mouse-phenotype.
org/software.html
STATISTICAL ANALYSIS
Statistical analysis was conducted using StatView (SAS Institute,
Cary, NC, USA). Data were analyzed by paired t-test, one-way
ANOVA, or two-way repeated measures ANOVA, unless noted
otherwise. Values in graphs are expressed as mean ± s.e.m.
Post-hoc comparisons were performed using Fisher’s protected
least significant difference (Fisher’s PLSD) multiple comparisons.
Genotype or drug × time was calculated by a repeated measures
ANOVA. The statistical treatment of data is described in the figure
legend.
RESULTS
HYPERACTIVITY AND IMPAIRED EMOTIONAL BEHAVIORAL
PHENOTYPE OF crmp1−/− MICE
To investigate the possible behavioral effects of CRMP1 defi-
ciency, we subjected crmp1−/− mice and their wt littermates to
a comprehensive behavioral test battery (Takao and Miyakawa,
2006). The crmp1−/− mice appeared healthy and showed no obvi-
ous differences in physical characteristics, as described previously
(Charrier et al., 2006). A small but significant decrease in body
weight of crmp1−/− mice was observed compared to wt con-
trol animals [28.675 ± 1.174 g in wt (n = 8), 24.825 ± 0.709 g
in crmp1−/− (n = 8), F(1, 14) = 7.875, p = 0.014 by one-way
ANOVA]. No significant differences in neuromuscular strength
(grip strength and wire hang tests) or sensorimotor reflexes (eye
blink, ear twitch, whisker touch, and righting reflex tests) were
apparent between wt and crmp1−/− mice (Table 1).
Examination of the locomotor activity of crmp1−/− mice in
several behavioral tasks revealed a hyperactivity phenotype of
the mutant animals. In 24-h home cage monitoring, the activ-
ity levels of crmp1−/− mice were significantly higher than those
of wt mice in both light and dark phases [Figure 1A; dark
period, F(1, 8) = 12.155, p = 0.0082; light period, F(1, 8) = 7.349,
p = 0.0266]. This hyperactivity phenotype was also observed in
an open field test. In crmp1−/− mice, the significant increases
in distance traveled and time spent in the central part were
FIGURE 1 | Increased locomotor activity of crmp1−/− mice in the
24-h home cage monitoring and the open field test. (A) Locomotor
activity of wt and crmp1−/− mice was monitored in their home cages
continuously for 1 week. The white and black areas above the graph
indicate light and dark periods, respectively. (B–E) The open field test
with total distance (B), vertical activity (C), center time (D), and
stereotypic counts (E). Statistic analysis was performed every 30min.
The p values indicate genotype effect in two-way repeated measures
ANOVA. Data are shown as mean ± s.e.m. for the indicated numbers
of mice. ∗p < 0.05.
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observed at 30 to 60min [F(1, 14) = 4.941, p = 0.0432] and at
90 to 120min [F(1, 14) = 5.108, p = 0.0403] of each test period,
when compared to wt mice (Figures 1B–E).
The hyperactivity phenotype of crmp1−/− mice was also
apparent in the elevated pulse maze test. Both wt and crmp1−/−
mice showed the typical pattern of favoring the closed arms.
However, the crmp1−/− mice spent more time in the central
part [Figure 2A; F(1, 13) = 6.250, p = 0.0266] and less time in
the enclosed arms [Figure 2B; F(1, 13) = 5.583, p = 0.0344] than
wt mice did. In addition, crmp1−/− mice showed a significant
decrease in immobility time compared withwt mice in the Porsolt
forced swim test [Figure 2C; day1, F(1, 14) = 6.776, p = 0.0209;
day2, F(1, 14) = 5.459, p = 0.0348]. The abnormal phenotypes of
crmp1−/− mice in these two tests may reflect anxiety-related and
depression-related behavior, respectively (Takao and Miyakawa,
2006). It is therefore possible that CRMP1 deficiency affects emo-
tional behavior. Consistent with this, in the open field test, signif-
icant increases were observed in distance traveled as well as time
spent in the central part, which reflects anxiety-related behavior
(Figures 1B,D). These data suggest that crmp1−/− mice exhibited
hyperactivity phenotype and/or impaired emotional behavioral
phenotype, which consequently affect locomotor activity of these
mice.
IMPAIRED LEARNING AND MEMORY OF crmp1−/− MICE
To assess whether the loss of CRMP1 was associated with
cognitive abnormalities, we performed various memory and
learning tests with crmp1−/− mice. In a contextual and cued
fear conditioning test, crmp1−/− mice did not show a signif-
icant difference in the levels of freezing during conditioning
[Figure 3A; F(1, 12) = 0.498, p = 0.4937]. In contrast, crmp1−/−
mice showed decreased levels of freezing in a contextual test but
not in a cued test 1 day after conditioning [Figure 3A; contex-
tual test, F(1, 12) = 4.936, p = 0.0463; cued test, F(1, 12) = 3.826,
p = 0.0742]. Freezing during the context test is attributed to hip-
pocampal or temporal lobe processes (Anagnostaras et al., 2001).
Deficits in freezing during both the context and cued tests are
indicative of amygdala dysfunction (Phillips and Ledoux, 1992;
Amorapanth et al., 2000). Our finding suggests that the function
of hippocampal and/or temporal lobe was selectively impaired in
crmp1−/− mice.
To examine the possible effect of CRMP1 deficiency on long-
term spatial memory, we subjected mice to the Barnes maze test.
Both crmp1−/− andwt mice learned to locate the escape hole dur-
ing the course of the training period (data not shown). Through
the training trials, there were no statistical differences between
crmp1−/− and wt mice in latencies [F(1, 14) = 0.47, p = 0.5044
by two-way repeated measures ANOVA] and errors [F(1, 14) =
0.107, p = 0.7484 by two-way repeated measures ANOVA] to
escape through the target hole. The probe trial was conducted
24 h after the last training session. Both crmp1−/− and wt mice
selectively located the correct target hole where the escape box
had been, and both crmp1−/− and wt mice spent significantly
more time around the target hole compared to the holes adjacent
to the target [Figure 3B; wt: t(7) = 3.216, p = 0.0147; crmp1−/−:
t(7) = 6.891, p = 0.0002]. To assess the long-term retention of
spatial memory in crmp1−/− mice, we also conducted probe
FIGURE 2 | Hyperactivity and/or impaired emotional behaviors of
crmp1−/− mice in stressful environments. (A,B) The time spent on
central part (A) and the close arms (B) in the elevated plus maze test. The p
values indicate genotype effect in one-way ANOVA. (C) Immobility rate in
the Porsolt forced swim test. The immobility time was recorded over a
10-min test period on day 1 and day 2. The p values indicate genotype
effect in two-way repeated measures ANOVA. Data are shown as mean ±
s.e.m. for the indicated numbers of mice. ∗p < 0.05.
tests 12 days after the last training trial. Again, wt mice selec-
tively located the correct target hole and spent significantly more
time compared to the adjacent holes, but crmp1−/− mice did
not [Figure 3B; wt: t(7) = 3.369, p = 0.0119; crmp1−/−: t(7) =
2.325, p = 0.053]. These results indicate that crmp1−/− mice
were impaired in memory retention rather than memory recall.
We also performed a T-maze forced alternation task, a task of
working memory. The crmp1−/− and wt mice did not show a sig-
nificant difference (Table 1), suggesting normal working memory
in crmp1−/− mice.
IMPAIRED PREPULSE INHIBITION AND EFFECT OF CHLORPROMAZINE
IN crmp1−/− MICE
We compared the efficiency of sensorimotor gating in crmp1−/−
and wt mice as assayed by the prepulse inhibition test. The
amplitudes of the startle response were similar in crmp1−/−
and wt mice [Figure 4A; F(1, 14) = 0.937, p = 0.3495]. The per-
centage of prepulse inhibition was significantly decreased in
crmp1−/− mice [Figure 4B, 110dB, F(1, 14) = 8.377, p = 0.0118;
120dB, F(1, 14) = 9.819, p = 0.0073], suggesting impaired sen-
sorimotor gating. Because disruption of prepulse inhibition is
a behavioral feature used to model one aspect of schizophre-
nia that is shared by several other disorders (Braff and Geyer,
1990; Paylor and Crawley, 1997), we treated crmp1−/− mice with
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FIGURE 3 | Impaired learning and memory of crmp1−/− mice. (A)
Contextual and cued fear conditioning test. Freezing rate during the training
phase, contextual test, and cued test were calculated. The p values indicate
genotype effect in two-way repeated measures ANOVA. (B) The probe trial
conducted 24 h or 12 days after the last training in the Barnes maze test.
Time spent around each hole was recorded. Time spent around target hole
and holes adjacent to the target was compared by paired t-test. Data are
shown as mean ± s.e.m. for the indicated numbers of mice. *p < 0.05.
chlorpromazine, a typical antipsychotic drug. Intraperitoneal
injection of 1mg/kg of chlorpromazine, which did not affect
startle response [Figure 4C; F(1, 29) = 0.1839, p = 0.6712], sig-
nificantly rescued impaired prepulse inhibition with a 110-dB
startle stimulus [Figure 4D; 110dB, F(1, 29) = 5.361, p = 0.0279;
120dB, F(1, 29) = 0.1559, p = 0.6959].
INCREASED METHAMPHETAMINE-INDUCED RELEASE OF DOPAMINE
IN crmp1−/− MICE
Because chlorpromazine is an effective antagonist of D2
dopamine receptors, it is possible that crmp1−/− mice exhibit
impaired dopaminergic function. To test this hypothesis, we
performed in vivo microdialysis to examine the extracellular
level of dopamine. Samples were collected from the prefrontal
cortex of freely moving mice, and the extracellular concentra-
tion of dopamine was determined by high-performance liq-
uid chromatography. We also measured the dopamine level
after the injection of methamphetamine (1mg/kg, i.p.). The
mean basal levels of dopamine before drug administration were
similar between wt and crmp1−/− mice [7.57 ± 1.35 pg/ml in
wt (n = 6), 8.71 ± 3.11 pg/ml in crmp1−/− (n = 7), F(1, 11) =
0.0955, p = 0.7584]. In contrast, the methamphetamine-induced
increase in dopamine concentration was significantly greater in
crmp1−/− mice [Figure 5; F(1, 11) = 9.7936, p = 0.0096]. These
data suggest that CRMP1 deficiency resulted in an increase in
methamphetamine-induced dopaminergic neurotransmission in
the prefrontal cortex.
DISCUSSION
Schizophrenia can be understood, in part, as abnormalities of
neuronal development (Bray et al., 2010). In this study, we
demonstrated that knockout of crmp1, a key gene in neu-
ronal development, caused aberrant behaviors such as increased
locomotor activity, impaired emotional behavioral responses,
and prepulse inhibition. Hyperactivity and impaired emotional
behavior are key endophenotypes of many human psychiatric dis-
orders, including schizophrenia (Gainetdinov et al., 2001), atten-
tion deficit hyperactivity disorder, and manic disorders (Paule
et al., 2000), and it is also characteristic of rodent models of
schizophrenia (Gainetdinov et al., 2001). The acute administra-
tion of methamphetamine in humans induces delusions and hal-
lucinations reminiscent of those associated with schizophrenia.
Furthermore, sensitivity to this drug is increased in individu-
als with schizophrenia (Lieberman et al., 1987) as well as in
several mouse models that manifest schizophrenia-like behav-
iors (Paterlini et al., 2005; Pillai-Nair et al., 2005; Sakae et al.,
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FIGURE 4 | Impaired prepulse inhibition and effect of chlorpromazine
in crmp1−/− mice. (A,B) Comparison between crmp1−/− and wt mice
in prepulse inhibition test with the amplitudes of the startle response
(A) and the percentage of prepulse inhibition (B). (C,D) Comparison
between chlorpromazine- and saline-treated crmp1−/− mice in prepulse
inhibition test with the amplitudes of the startle response (C) and the
percentage of prepulse inhibition (D). The p values indicate genotype
(A,B) or drug (C,D) effect in two-way repeated measures ANOVA. Data
are shown as mean ± s.e.m. for the indicated numbers of mice.
∗p < 0.05, ∗∗p < 0.01.
2008). Furthermore, the crmp1−/− mice exhibited an increase
in methamphetamine-induced dopaminergic neurotransmission
in the prefrontal cortex (Figure 5), whose dysfunction has been
shown to be related to many neuropsychiatric disorders (Bray
et al., 2010). The impaired prepulse inhibition, another typical
endophenotype of schizophrenia (Braff and Geyer, 1990; Paylor
and Crawley, 1997), of crmp1−/− mice was rescued by the admin-
istration of chlorpromazine (Figure 4). These data suggest that
the behavioral abnormality of crmp1−/− mice is closely related
to impaired dopaminergic signaling, which is one of the most
common causes of schizophrenia (Ross et al., 2006). It is known
that negative symptoms are not modeled equivalently to pos-
itive symptoms. In our behavioral test battery, the crmp1−/−
mice did not show an anhedonic or depressive-like behavior.
Furthermore, thesemice showed no abnormality in social interac-
tions (Table 1). Thus, the crmp1−/− mice exhibited some behav-
ioral phenotypes that are related to the positive but not negative
symptoms of schizophrenia.
Most rodent models of schizophrenia tend to replicate aspects
of the positive symptoms of schizophrenia, such as hyperactiv-
ity, probably reflecting enhanced mesolimbic dopamine function
(Breier et al., 1997; Laruelle et al., 1999). In rodents, chronic
amphetamine administration induces a persistent sensitization,
exaggerating the hyperactivity caused by acute amphetamine
challenge (Featherstone et al., 2007), and there have been some
reports of genetic models that show hyperdopaminergic func-
tions (Paterlini et al., 2005; Pillai-Nair et al., 2005; Sakae et al.,
2008). In addition to a hyperdopaminergic phenotype, crmp1−/−
mice show a poor dendritic trees and a low density of dendritic
spines in the cerebral cortex (Yamashita et al., 2007). In human
Schizophrenic patients, a marked reduction in dendritic spine
density and glutamate receptor immunoreactivity is observed
in cortical areas of schizophrenic subjects (Glantz and Lewis,
2000; Kolluri et al., 2005; Garey et al., 2006; Garey, 2010). Thus,
the phenotypes of crmp1−/− mice are consistent with those of
schizophrenic patients either from a functional or morpholog-
ical point of view, suggesting that crmp1−/− mice may be a
comprehensive model that more adequately replicates deficits in
schizophrenic symptoms.
The underlying mechanism of the crmp1−/− mouse pheno-
type is unknown. CRMP1 is phosphorylated by Cdk5, a major
protein kinase that regulates dendritic spine maturation and
dopamine signaling in neurons (Bibb et al., 1999; Morabito et al.,
2004; Cole et al., 2006; Yamashita et al., 2007). Cultured cortical
neurons from both crmp1−/− and cdk5−/− mice show abnormal
dendritic spine morphology. In addition, the abnormal dendritic
spine morphology in crmp1−/− cultured cortical neurons is res-
cued by introduction of wt CRMP1 but not a CRMP1 mutant
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FIGURE 5 | Enhanced methamphetamine-induced release of dopamine
(DA) of crmp1−/− mice. The extracellular concentration of DA in the
prefrontal cortex of freely moving mice was determined by in vivo
microdialysis. After collection of basal fractions, methamphetamine
(1mg/kg, i.p) was administrated at time 0. Dopamine concentration was
expressed as a percentage of the average of that in the six baseline
fractions before drug administration. Statistic analysis was performed
before and after the drug administration. The p values indicate genotype
effect in two-way repeated measures ANOVA. Data are shown as mean ±
s.e.m. for the indicated numbers of mice. ∗p < 0.01.
that cannot be phosphorylated by Cdk5 (Yamashita et al., 2007),
demonstrating that CRMP1 is a major substrate of Cdk5 to
regulate neuronal development. Thus the schizophrenia-related
behaviors seen in crmp1−/− mice may be caused by the disrup-
tion of Cdk5-CRMP1 signaling. In fact, mice treated with Cdk5
inhibitors and CA1-specific cdk5 conditional knockoutmice show
decreased levels of freezing in a contextual test but not in a
cued test (Fischer et al., 2002; Guan et al., 2011). This phe-
notype is similar to that seen in crmp1−/− mice (Figure 3A).
Interestingly, the expression level of p35, a neuron-specific acti-
vator of Cdk5, is decreased in both prefrontal cortex and hip-
pocampus of schizophrenia post-mortem brains (Engmann et al.,
2011).
The tyrosine phosphorylation of CRMP1 may also be involved
in behavioral abnormalities of crmp1−/− mice. CRMP1 is tyro-
sine phosphorylated by Fyn downstream of Reelin signaling
(Yamashita et al., 2006). Reelin signaling also has been impli-
cated in various neurodevelopmental disorders (Fatemi, 2005).
The mRNA and protein expression of Reelin are decreased in
patients with schizophrenia and bipolar disorder (Impagnatiello
et al., 1998; Guidotti et al., 2000). Heterozygous reeler mutation
mice, which show a 50% reduction in Reelin protein and mRNA,
exhibit decreased prepulse inhibition (Tueting et al., 1999), as we
observed in crmp1−/− mice (Figure 4). Thus, it is possible that
behavioral abnormalities of crmp1−/− mice are related to CRMP1
phosphorylation at tyrosine residue(s).
Recently, several crmp genes (crmp2: 8p22-p21; crmp3: 10q26;
crmp4: 5q32) were located to chromosomal regions associated
with schizophrenia (Ross et al., 2006). Similar to that link-
age study, crmp1 or crmp2 gene polymorphisms and abnor-
mal CRMP1 or CRMP2 protein levels have been found in
schizophrenia (Edgar et al., 2000; Johnston-Wilson et al., 2000;
Hong et al., 2005; Beasley et al., 2006; Bader et al., 2012). In
addition, aberrant accumulation of insoluble forms of CRMP1
is also observed in brains from schizophrenic patients (Bader
et al., 2012). These findings may be inconsistent with our present
finding that crmp1−/− mice showed schizophrenia-related behav-
iors. The reasons for the apparent discrepancy between human
and animal subjects are unknown. However, it is possible that
the presence of these insoluble forms of CRMP1 may lead to
the loss of function of CRMP1 in the human brains. In this
case, our observation of behavioral abnormalities in crmp1−/−
mice may be consistent with findings obtained in specimens from
schizophrenia patients (Bader et al., 2012). Interestingly, lym-
phoblastoid cell lines derived from schizophrenia patients show
an abnormal level of CRMP1 expression, suggesting its poten-
tial role as a blood-based diagnostic marker (Bader et al., 2012).
Taken together, these findings raise the possibility that CRMP1
may be involved in the pathophysiology in schizophrenia.
In conclusion, our results suggest that CRMP1 is associated
with some of the symptoms of schizophrenia and/or some related
disorders. Although future studies are need to determine whether
crmp1−/− mouse is a clinically relevant model of schizophrenia,
our results suggest that crmp1−/− mouse is useful in exploring
basic mechanisms that may contribute to some of the symptoms
of this neuropsychiatric disorder.
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